6 citations
,
September 2020 in “African Journal of Urology” This study found that prostate size varies significantly among different ethnic groups in South-Kivu, with the Lega having larger prostate volumes compared to other groups.
This dissertation found that finasteride reduced prostate volume by 6.3% and total serum PSA by 10.51% in young patients over one year.
October 2015 in “Digital Library of Theses and Dissertations (Universidade de São Paulo)” This study observed smaller reductions in PSA levels in men under 40 taking finasteride 1mg/day compared to older age groups, without changes in testosterone levels.
March 2010 in “The Journal of Urology” This study found that men with early-onset androgenetic alopecia had larger prostate volumes and lower urinary flow rates compared to those without the condition, suggesting a potential link between AGA and urinary symptoms.
October 2010 in “Journal of Men's Health” Larger prostate size in older men may be linked to poorer semen quality and fertility issues.
34 citations
,
January 2000 in “Journal of Andrology” This study found no difference in CAG repeat length between Chinese and Australian men, refuting the hypothesis that this polymorphism and central prostate zone volume are markers of long-term androgen sensitivity.
1 citations
,
January 2002 in “El Servicio de Difusión de la Creación Intelectual (National University of La Plata)” This study found that finasteride at a low dose of 0.1 mg/kg significantly reduced prostate size in male dogs with benign prostatic hyperplasia without causing toxic side effects.
September 2011 in “Urology” This study explores the clinical significance of the intravesical prostatic protrusion/prostate volume ratio in diagnosing bladder outlet obstruction but reports no new results.
28 citations
,
August 2011 in “Journal of The American Academy of Dermatology” This study found that men with early-onset androgenetic alopecia had significantly larger prostate volumes and lower urinary flow rates compared to healthy controls, suggesting a possible link between AGA and prostate-related urinary symptoms.
21 citations
,
January 1998 in “Urologia internationalis” This study found that combining dibenyline and finasteride for symptomatic BPH treatment offered modest improvements with fewer additional side effects compared to each drug alone.
19 citations
,
October 2018 in “PLOS ONE” This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.
5 citations
,
September 2012 in “The Journal of Urology” This article discusses androgenetic alopecia as a potential early marker for benign prostatic hyperplasia but reports no new clinical findings.
January 2018 in “Universidad Privada Antenor Orrego” This study found that androgenic alopecia may serve as an early marker for benign prostatic hyperplasia.
October 2006 in “Aging Health” This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.
April 2012 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Early hair loss in men could be a sign of non-cancerous prostate enlargement, and treating hair loss early might help prevent prostate issues later.
March 2012 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Hair loss can be an early sign of prostate enlargement.
15 citations
,
December 2006 in “Clinical interventions in aging” This analysis of the Prostate Cancer Prevention Trial found that finasteride reduces prostate cancer risk by nearly 25% and enhances the PSA test's ability to detect prostate cancer and high-risk diseases.
September 2011 in “Urology” This study aimed to estimate the value of urine prostate specific antigen (uPSA) as a marker for benign prostatic hyperplasia (BPH) but reported no new clinical findings.
235 citations
,
September 2004 in “The Journal of urology/The journal of urology” This review discusses the role of dihydrotestosterone in benign prostatic hyperplasia and reports no new results; the authors highlight 5alpha-reductase inhibitors as a well-established treatment option.
35 citations
,
May 2020 in “Frontiers in Pharmacology” This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.
33 citations
,
January 2009 in “Journal of Cutaneous and Aesthetic Surgery” This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.
3 citations
,
January 2015 in “DOAJ (DOAJ: Directory of Open Access Journals)” This study found no relationship between androgenic alopecia and parameters such as PSA level, IPSS, and prostate volume in men over 50.
2 citations
,
February 2006 in “Mayo Clinic Proceedings” Finasteride is effective for hair loss and may help prevent prostate cancer without increasing high-grade cancer risk.
1 citations
,
January 2019 in “PubMed” This study found no correlation between androgenic alopecia and lower urinary tract symptoms or prostate volume in men who underwent a Green Light Laser Vaporization Procedure of the prostate.
1 citations
,
January 2016 in “ARC Journal of Urology” This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.
June 2023 in “Research Square (Research Square)” This study found that among male Han Chinese, a higher polygenic risk score was linked to increased risk and poorer treatment outcomes for benign prostatic hyperplasia.
January 2020 in “Journal of Men s Health” In this study of BPH patients with testosterone deficiency, the combination of TU and dutasteride reduced prostate volume and improved testosterone-related symptoms but was less effective for sexual function compared to TU alone, indicating caution in using dutasteride for those with sexual dysfunction concerns.
April 2010 in “The Journal of Urology” Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.
January 2017 in “Indian journal of health sciences and biomedical research KLEU” This study found no association between androgenetic alopecia and increased prostate volume or serum PSA levels in male patients aged 25–45.
This study found that early-onset androgenetic alopecia is associated with higher prevalence of metabolic syndrome, atheroma plaques, and urinary symptoms related to prostate growth compared to controls.